GlobalData Plc

Singapore’s pharmaceutical market is expected to expand from $903 million in 2016 to $1.15 billion by 2021, according to GlobalData, a leading data and analytics company.

The company’s latest report: ‘CountryFocus: Singapore’ reveals that Singapore’s healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research facilities. However,  the market is small in comparison to those of other developed countries, primarily due to the small population.

In 2010, Singapore was ranked fourth globally for its healthcare infrastructure, according to the Institute for Management Development. Efficient healthcare infrastructure and increasing public healthcare expenditure are expected to drive the market.

Sama Khan, Healthcare Analyst at GlobalData, comments: “Singapore develops pharmaceuticals and medical devices at the medical technology hubs MedTech, Biopolis and Tuas Biomedical Park. The country has emerged as a regional hub for the manufacture and R&D activities of multinational pharmaceutical companies, and offers excellent opportunities for biomedical science companies via a pro-business environment, low unit labor costs, low corporate tax and strong government support.”

The medical device market is expected to grow as Singapore strengthens its position as the region’s healthcare hub. In 2015 the medical device market contributed $1.69 billion to Singapore’s output.

Khan continues: “While medical devices are imported primarily from the US, Japan and Germany, products such as syringes, catheters and research instruments are manufactured domestically. There are over 30 medical technology companies in Singapore that have set up commercial-scale plants to produce medical devices for the regional and global markets.”

Singapore offers a solid economy for investors due to the stable government and its initiatives. In 2016, Business Environment Risk Intelligence (BERI) ranked Singapore first among 50 countries as an investment destination. The country continues to boost its knowledge-based, free market economy, which is primarily dependent upon exports. It provides a corruption-free and open market environment.

Khan concludes: “The government offers universal healthcare coverage through a mixed financing system. Per-capita government expenditure on health increased from $1,656 in 2009 to $2,752 in 2014 according to the World Bank, and is expected to increase further over time due to the anticipated growth of the elderly population.”

Information based on GlobalData’s report: CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF